Gianluca Laus

Osimertinib versus platinum–pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis

Vassiliki A. Papadimitrakopoulou, Tony Mok, Ji‐Youn Han et al. · Annals of Oncology · 2020 · 276 citations · Full text

Medicine, Oncology, Pharmacology +15

Analysis of resistance mechanisms to osimertinib in patients with EGFR T790M advanced NSCLC from the AURA3 study

Vassiliki A. Papadimitrakopoulou, Yi‐Long Wu, J. Y. Han et al. · Annals of Oncology · 2018 · 253 citations

Medicine, Oncology, Pharmacology +12

Osimertinib Plus Durvalumab versus Osimertinib Monotherapy in EGFR T790M–Positive NSCLC following Previous EGFR TKI Therapy: CAURAL Brief Report

James Chih‐Hsin Yang, Frances A. Shepherd, Dong‐Wan Kim et al. · Journal of Thoracic Oncology · 2019 · 210 citations · Full text

Medicine, Oncology, Pharmacotherapy +15

Analysis of acquired resistance mechanisms to osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer from the AURA3 trial

Juliann Chmielecki, Tony Mok, Yi‐Long Wu et al. · Nature Communications · 2023 · 173 citations · Full text

Medicine, Oncology, Pharmacology +17

Epidermal growth factor receptor mutation analysis in tissue and plasma from the AURA3 trial: Osimertinib versus platinum‐pemetrexed for T790M mutation‐positive advanced non–small cell lung cancer

Vassiliki A. Papadimitrakopoulou, Ji‐Youn Han, Myung‐Ju Ahn et al. · Cancer · 2019 · 121 citations · Full text

Medicine, Molecular Medicine, Oncology +17